Alendronate
Product Images NDC 10135-697

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Alendronate (NDC 10135-697). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Molecular Formula Of Alendronate Sodium Is C4h12nnao7p2•3h2o And Its Formula Weight Is325.12. The Structural Formula Is: (Alendronate Sodium Tablets 01)

Not available.*

FDA Label Image

Figure 1:cumulative Incidence Of Hip Fractures In The Three-year Study Of Fit (patients With Radiographic Vertebral Fracture At Baseline) (Alendronate Sodium Tablets 02)

FDA Label Image

Figure 2: Osteoporosis Treatment Studies In Postmenopausal Womenincrease In Bmd Alendronate 10 mg/day At Three Years (Alendronate Sodium Tablets 03)

FDA Label Image

Figure 3: Figure 3: Osteoporosis Treatment Studies In Postmenopausal Womentime Course Of Effect Of Alendronate 10 mg/day Versus Placebo: Lumbar Spine Bmd Percent Change From Baseline (Alendronate Sodium Tablets 04)

FDA Label Image

Figure 4 (Alendronate Sodium Tablets 05)

The text contains a table with the columns "Change in BMD from Baseline 2-Year Study" and "Change in BMD from Baseline 3-Year Study" and rows of data labelled "Alendronate Sodium 5mg/day" and "Placebo". The table shows percentages of mean change in BMD in different parts of the body including spine, neck, body, femoral trochanter, and total. There is no clear description or purpose provided for this data.*

FDA Label Image

Figure 5 (Alendronate Sodium Tablets 06)

The text appears to be a table or chart showing the increase in bone mineral density (BMD) for patients with glucocorticoid treatment who were given the medication Alendronate at a dose of 5 mg/day for one year. The table shows the mean 9% increase in BMD relative to a placebo, with separate increases shown for the lumbar spine, femoral neck, and trochanter. This information is likely from a clinical trial or study evaluating the efficacy of Alendronate in improving BMD in patients with glucocorticoid treatment.*

FDA Label Image

Figure 6: (Alendronate Sodium Tablets 07)

This text appears to be a part of a study on Paget's disease of bone. The study evaluates the effect of Alendronate 40mg/day on serum alkaline phosphatase compared to Placebo or Etidronate 400mg/day. The study is a multinational trial and a US Study. The graph shows the results at different time intervals (in months).*

FDA Label Image

Principal Display Panel- 35 mg Tablet Blister Pack Carton4 Tabletsrx Onlyndc 10135-0696-44once Weekly (Alendronate Sodium Tablets 08)

FDA Label Image

Principal Display Panel- 35 mg Tablet Blister Pack Carton12 (3×4) Unit-of-us E Tabletsrx Onlyndc 10135-0696-12once Weekly (Alendronate Sodium Tablets 09)

This is a description for Alendronate Sodium Tablets, USP 35 mg. It is a weekly medication for adults who suffer from osteoporosis. It contains 12 tablets per package and each tablet is 35mg in strength. The recommended dosage is one 35mg tablet per week, accompanied by a glass of water. The drug comes with a prescription label and should only be dispensed by a pharmacist. The medication is manufactured by Mtx Pharmaceuticals in New Castle, CA and distributed in the USA.*

FDA Label Image

Principal Display Panel- 70 mg Tablet Blister Pack Carton4 Tabletsrx Onlyndc 10135-0697-44once Weekly (Alendronate Sodium Tablets 0a)

This appears to be a product label for Alendronate Sodium Tablets, used to treat bone loss. The label includes dosage instructions, manufacturer information, and warnings about potential side effects. It is recommended to store the medication at room temperature.*

FDA Label Image

Principal Display Panel- 70 mg Tablet Blister Pack Carton12 (3×4) Unit-of-use Tabletsrx Onlyndc 10135-0697-12 Once Weekly (Alendronate Sodium Tablets 0b)

This appears to be a description of a medication called "Alendronate Sodium Tablets". Each tablet contains 70mg of the active ingredient, sodium alendronate, and is meant to be taken once a week as indicated on the prescription label. The manufacturer is listed as Marx Pharmaceuticals and the tablets come in a pack of 12. The rest of the text is illegible or fragmented and is not-usable to generate any further information.*

FDA Label Image

Principal Display Panel- 70 mg Tablet Blister Pack Carton20 (2×10) Unit-dose Tabletsrx Onlyndc 10135-0697-20once Weekly (Alendronate Sodium Tablets 0c)

This is the description: "Once Weekly Alendronate Sodium Tablets, USP 70 mg is a medication manufactured by Marx Pharmaceuticals. It comes in tablet form and is intended for adults. The usual adult dosage of this medication is one 70 mg tablet once a week. It contains 1.37 mg of alendronate sodium per tablet. This medication requires a prescription label. For further information, refer to the enclosed medication guide. Keep all drugs out of reach of children and store at 20°-25°C (68-77°F) with excursions permitted to 15°-30°C (59°-86°F)."*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.